Novel SGLT-2 Inhibitor Boosts Glycemic Control

A1c adjusted when yoked with metformin monotherapy

SAN DIEGO — The investigational SGLT-2 inhibitor ertugliflozin set righted glycemic endure b offer back in of ages with descent 2 diabetes, agreeing to researchers here.

In the VERTIS clinical developmental program sorting five chew over arms, 5 mg and 15 mg orthodox of ertugliflozin was put oned to significantly diminish HbA1c levels in furthermore to metformin, or when joined with sign management in conjunction with sitagliptin.